Pharmacogenomics and public health

Public Health Genomics

Volumn 12, Issue 3, 2009, Pages 131-133

  Veenstra, D ^a   Burke, W ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; WARFARIN;

BLEEDING; BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; EARLY CANCER; GENETIC RISK; GENETIC VARIABILITY; HEALTH CARE SYSTEM; HUMAN; PATIENT CARE; PHARMACOGENOMICS; PRIORITY JOURNAL; PUBLIC HEALTH; RECURRENCE RISK; RECURRENT CANCER; REIMBURSEMENT; SHORT SURVEY; ARTICLE; PHARMACOGENETICS;

HUMANS; PHARMACOGENETICS; PUBLIC HEALTH;

EID: 64549101706     PISSN: 16624246     EISSN: None     Source Type: Journal    
DOI: 10.1159/000189624     Document Type: Short Survey

References (14)

1. Carlson RJ: The disruptive nature of personalized medicine technologies: implications for the health care system. Public Health Genomics 2009;12:180-184.
2. Garrison LP: Will pharmacogenomics disrupt the US health care system? No. Public Health Genomics 2009;12:185-190.
3. Haga SB, Warner LR, O'Daniel J: The potential of a placebo/nocebo effect in pharmacogenetics. Public Health Genomics 2009;12:158-162.
4. Lee SSJ: Pharmacogenomics and the challenge of health disparities. Public Health Genomics 2009;12:170-179.
5. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
6. Wang L, Weinshilboum R: Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006;25:1629-1638.
7. Limdi NA, Veenstra DL: Warfarin pharmacogenetics. Pharmacotherapy 2008;28:1084-1097.
8. Goetz MP, Kamal A, Ames MM: Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008;83:160-166.
9. Guessous I, Gwinn M, Yu W, Yeh J, Clyne M, Khoury MJ: Trends in pharmacogenomic epidemiology: 2001-2007. Public Health Genomics 2009;12:142-148.
10. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C: Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med 2007;9:695-704.
11. Deverka PA: Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 2009;12:149-157.
12. Gurwitz D, Zika E, Hopkins MM, Gaisser S, Ibarreta D: Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 2009;12:134-141.
13. Avard D, Silverstein T, Sillon G, Joly Y: Researchers' perceptions of the ethical implications of pharmacogenomics research with children. Public Health Genomics 2009;12:191-201.
14. Issa AM, Tufail W, Hutchinson J, Tenorio J, Baliga MP: Assessing patient readiness for the clinical adoption of personalized medicine. Public Health Genomics 2009;12:163-169.